The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.

The present invention describes a viral RNA expression plasmid and a method for obtaining viral particles based on said plasmids comprising transfecting animal cells with an expression vector or a set of expression vectors capable of expressing a nucleoprotein and RNA-dependent polymerase RNA; and transfecting the animal cell with an expression vector or a set of expression vectors with nucleotide sequences encoding recombinant RNA molecules.

The present invention relates to methods of replicating viruses in vitro. In particular, the invention relates to a genetically modified population of cells, and/or a population of cells treated with an exogenous compound, wherein the cells are capable of producing more virus than cells lacking the genetic modification and/or lacking treatment with the exogenous compound. The invention also relates to methods of producing populations of such cells, as well as the use of the viruses obtained to prepare vaccine compositions.

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.

Provided herein are methods of producing a heterologous polypeptide and compositions comprising same.

Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.

This disclosure provides a platform for making live, attenuated viruses. This disclosure also provides methods of using the live, attenuated viruses.

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified. neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.

In a method for processing biological materials for flow cytometry evaluation for virus particles, a mixture including biological material and purification particles is centrifuged to prepare a centrifuged composition including a supernatant that may be further processed prior to the flow cytometry evaluation. The purification particles include porous cores functionalized to capture smaller-size impurities in a biological material sample and a porous size-exclusion shell surrounding the core to exclude larger-size components of the biological material from entering into the core. Multiple samples may be processed in multi-sample processing units. A product may contain a sealed container with the unit quantity of purification particle in a storage liquid and a kit may include such a sealed container and a centrifugal filter.